Table 1

 Patient demographics and baseline characteristics

Peginterferon alfa-2a (40KD) + ribavirin
24 week (n = 28)48 weeks (n = 284)Total (n = 312)
BMI, body mass index; HCV, hepatitis C virus.
Monotherapy, interferon alfa-2b, interferon alfa-2a, interferon alfacon-1
Combination therapy, interferon alfa-2b plus ribavirin.
Sex (n (%) male)18/28 (64.3)202/284 (71.1)220/312 (70.5)
Mean age (y)
    Non-responders45.147.347.2
    Relapsers48.347.147.3
Caucasian (n (%))
    Non-responders11/13 (84.6)178/199 (89.9)189/312 (60.6)
    Relapsers15/15 (100)76/85 (89.4)91/312 (29.2)
Asian (n (%))
    Non-responders1/13 (7.7)13/199 (6.5)14/312 (4.5)
    Relapsers0/15 (0)7/85 (8.2)7/312 (2.2)
Other race (n (%))
    Non-responders1/13 (7.7)8/199 (4.0)9/312 (2.9)
    Relapsers0/15 (0)2/85 (2.4)2/312 (0.6)
Mean BMI (kg/m2)
    Non-responders24.727.727.5
    Relapsers27.127.327.3
HCV genotype (n (%))
    Non-responders
        10/13 (0.0)184/199 (92.5)184/312 (86.8)
        2 or 313/13 (100.0)15/199 (7.5)28/312 (13.2)
    Relapsers
        10/15 (0.0)69/85 (81.2)69/312 (69.0)
        2 or 315/15 (100.0)16/85 (18.8)31/312 (31.0)
HCV viral load (IU/ml) (n (%))
    Non-responders
        >850 0001/13 (7.7)63/199 (31.7)64/312 (30.2)
        ⩽850 00012/13 (92.3)136/199 (68.3)148/312 (69.8)
    Relapsers
        >850 0006/15 (40.0)34/85 (40.0)40/312 (40.0)
        ⩽850 0009/15 (60.0)51/85 (60.0)60/312 (60.0)
Bridging fibrosis (F3) (n (%))
    Non-responders5/13 (38.5)43/199 (21.6)48/312 (15.4)
    Relapsers1/13 (7.7)24/199 (12.1)25/312 (8.0)
Cirrhosis (F4)
    Non-responders2/15 (13.3)56/85 (65.9)58/312 (18.6)
    Relapsers7/15 (46.7)16/85 (18.8)23/312 (7.4)
Previous HCV therapy (n (%))
    Non-responders
        Monotherapy5/13 (38.5)40/199 (20.1)45/312 (21.2)
        Combination therapy8/15 (61.5)159/85 (79.9)167/312 (78.8)
    Relapsers
        Monotherapy8/13 (53.3)15/199 (17.7)23/312 (23.0)
        Combination therapy7/15 (46.7)70/85 (82.4)77/312 (77.0)